MENU
+Compare
BBC
ETF ticker: NYSE ARCA
AS OF
Jan 21 closing price
Price
$22.46
Change
+$0.63 (+2.89%)
Net Assets
7.65M

BBC stock forecast, quote, news & analysis

Category: @Health
BBC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for BBC with price predictions
Jan 08, 2025

BBC saw its Stochastic Oscillator recovers from the overbought zone

The Stochastic Oscillator for BBC moved out of overbought territory on January 08, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 58 similar instances where the indicator exited the overbought zone. In of the 58 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BBC as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 50-day moving average for BBC moved below the 200-day moving average on January 02, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BBC entered a downward trend on January 08, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BBC just turned positive on January 02, 2025. Looking at past instances where BBC's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BBC advanced for three days, in of 293 cases, the price rose further within the following month. The odds of a continued upward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Arrowhead Pharmaceuticals (NASDAQ:ARWR), Novavax (NASDAQ:NVAX).

Industry description

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

Market Cap

The average market capitalization across the Virtus LifeSci Biotech Clinical Trls ETF ETF is 1.76B. The market cap for tickers in the group ranges from 41.95M to 16.3B. SMMT holds the highest valuation in this group at 16.3B. The lowest valued company is RAPT at 41.95M.

High and low price notable news

The average weekly price growth across all stocks in the Virtus LifeSci Biotech Clinical Trls ETF ETF was 4%. For the same ETF, the average monthly price growth was -8%, and the average quarterly price growth was -23%. IBRX experienced the highest price growth at 39%, while SANA experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the Virtus LifeSci Biotech Clinical Trls ETF ETF was -16%. For the same stocks of the ETF, the average monthly volume growth was -44% and the average quarterly volume growth was 27%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 84
Price Growth Rating: 69
SMR Rating: 94
Profit Risk Rating: 88
Seasonality Score: 5 (-100 ... +100)
View a ticker or compare two or three
BBC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
501 Madison Avenue, Suite 501New YorkNew York
Phone
(212) 593-4383
Web
N/A